The China Paradox in LEAP-012 Trial
Liver Cancer · 18.05.2026 · 15 (3) · 329-336
DOI: 10.1159/000552537 ↗Kurz gefasst
Editorial in der Zeitschrift Liver Cancer, online erschienen am 18.05.2026. Verfasst von Masatoshi Kudo. Beteiligte Einrichtung: Editor-in-Chief, Liver Cancer, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Sakai, Osaka, Japan. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
comparing lenvatinib plus pembrolizumab combined with TACE and dual placebo plus TACE in the global cohort and the Chinese subgroup. PFS was longer in the Chinese subgroup than in the global cohort in the combination arm, whereas the opposite pattern was observed in the dual placebo plus TACE arm, with shorter PFS in the Chinese subgroup.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Editor-in-Chief, Liver Cancer, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Sakai, Osaka, Japan.
Zitieren
APA
Kudo, M. (2026). The China Paradox in LEAP-012 Trial. Liver Cancer, 15(3), 329-336. https://doi.org/10.1159/000552537
Vancouver
Kudo M. The China Paradox in LEAP-012 Trial. Liver Cancer. 2026;15(3):329-336. doi:10.1159/000552537
BibTeX
@article{Kudo2026,
author = {Kudo, Masatoshi},
title = {The China Paradox in LEAP-012 Trial},
journal = {Liver Cancer},
year = {2026},
volume = {15},
number = {3},
pages = {329--336},
doi = {10.1159/000552537}
}
EUVIMED